Table 2.

Summary of objective response based on investigator assessment per RECIST v1.1 in intention-to-treat population

	Pembrolizumab + Epacadostat n = 35	Pembrolizumab Monotherapy n = 19	EXTREME n = 35
Objective response rate, n (%) [95% CI]	11 (31) [17–49]	4 (21) [6–46]	12 (34) [19–52]
Best overall response, n (%)
Complete response	3 (9)	0	2 (6)
Partial response	8 (23)	4 (21)	10 (29)
Stable disease	8 (23)	6 (32)	15 (43)
Progressive disease	13 (37)	9 (47)	5 (14)
No assessmenta	3 (9)	0	3 (9)

Responses are based on investigator assessments per RECIST v1.1 without confirmation using all available scans

CI Confidence interval, RECIST v1.1 Response Evaluation Criteria in Solid Tumors version 1.1

^aNo post-baseline assessments were available for response evaluation